Advicenne S.A. (ALDVI.PA)
EUR 1.67
(0.12%)
EUR 1.67
(0.12%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 17.42 Million EUR | -7.09% |
| 2022 | 18.75 Million EUR | 49.59% |
| 2021 | 12.53 Million EUR | -9.13% |
| 2020 | 13.79 Million EUR | 2975.09% |
| 2019 | 448.7 Thousand EUR | 6.86% |
| 2018 | 419.9 Thousand EUR | -40.16% |
| 2017 | 701.67 Thousand EUR | -78.85% |
| 2016 | 3.31 Million EUR | -2.36% |
| 2015 | 3.39 Million EUR | 1162.83% |
| 2014 | 269 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 17.8 Million EUR | 2.18% |
| 2024 Q2 | 17.8 Million EUR | 0.0% |
| 2023 Q1 | 18.61 Million EUR | -0.75% |
| 2023 FY | 17.42 Million EUR | -7.09% |
| 2023 Q4 | 17.42 Million EUR | -0.94% |
| 2023 Q3 | 17.59 Million EUR | -6.08% |
| 2023 Q2 | 18.73 Million EUR | 0.62% |
| 2022 FY | 18.75 Million EUR | 49.59% |
| 2022 Q4 | 18.75 Million EUR | 0.64% |
| 2022 Q3 | 18.63 Million EUR | 40.0% |
| 2022 Q2 | 13.31 Million EUR | 0.9% |
| 2022 Q1 | 13.19 Million EUR | 5.22% |
| 2021 Q3 | 12.47 Million EUR | -9.83% |
| 2021 Q1 | 14.1 Million EUR | 2.25% |
| 2021 FY | 12.53 Million EUR | -9.13% |
| 2021 Q4 | 12.53 Million EUR | 0.52% |
| 2021 Q2 | 13.83 Million EUR | -1.95% |
| 2020 FY | 13.79 Million EUR | 2975.09% |
| 2020 Q4 | 13.79 Million EUR | 1.03% |
| 2020 Q1 | 8.93 Million EUR | 1890.19% |
| 2020 Q2 | 9.08 Million EUR | 1.68% |
| 2020 Q3 | 13.65 Million EUR | 50.41% |
| 2019 FY | 448.7 Thousand EUR | 6.86% |
| 2019 Q2 | 1.49 Million EUR | 5.94% |
| 2019 Q1 | 1.41 Million EUR | 236.98% |
| 2019 Q4 | 448.7 Thousand EUR | -69.12% |
| 2019 Q3 | 1.45 Million EUR | -3.07% |
| 2018 Q4 | 419.9 Thousand EUR | 0.0% |
| 2018 FY | 419.9 Thousand EUR | -40.16% |
| 2018 Q3 | 419.9 Thousand EUR | -17.34% |
| 2018 Q2 | 508 Thousand EUR | 0.0% |
| 2018 Q1 | 508 Thousand EUR | -27.6% |
| 2017 Q2 | 709 Thousand EUR | -9.68% |
| 2017 Q3 | 702 Thousand EUR | -0.99% |
| 2017 Q4 | 701.67 Thousand EUR | -0.05% |
| 2017 FY | 701.67 Thousand EUR | -78.85% |
| 2017 Q1 | 785 Thousand EUR | -76.33% |
| 2016 Q3 | 3.78 Million EUR | 0.0% |
| 2016 Q1 | - EUR | 0.0% |
| 2016 Q4 | 3.31 Million EUR | -12.34% |
| 2016 FY | 3.31 Million EUR | -2.36% |
| 2015 FY | 3.39 Million EUR | 1162.83% |
| 2014 FY | 269 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -414.012% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 68.583% |
| Adocia SA | 13.08 Million EUR | -33.137% |
| Aelis Farma SA | 4.03 Million EUR | -331.526% |
| Biophytis S.A. | 8.27 Million EUR | -110.701% |
| genOway Société anonyme | 7.23 Million EUR | -140.896% |
| IntegraGen SA | 1.12 Million EUR | -1449.254% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1352.083% |
| Neovacs S.A. | 650 Thousand EUR | -2580.769% |
| NFL Biosciences SA | 62.17 Thousand EUR | -27926.185% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -299.976% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -541.37% |
| Sensorion SA | 2.86 Million EUR | -507.4% |
| Theranexus Société Anonyme | 3.64 Million EUR | -378.312% |
| TME Pharma N.V. | 1.16 Million EUR | -1394.425% |
| Valbiotis SA | 6.87 Million EUR | -153.344% |
| TheraVet SA | 1.15 Million EUR | -1402.327% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -93.654% |
| argenx SE | 18.1 Million EUR | 3.757% |
| BioSenic S.A. | 28.16 Million EUR | 38.124% |
| Celyad Oncology SA | 902 Thousand EUR | -1831.818% |
| DBV Technologies S.A. | 13.01 Million USD | -33.847% |
| Galapagos NV | 9.59 Million EUR | -81.586% |
| Genfit S.A. | 70.17 Million EUR | 75.17% |
| GeNeuro SA | 7.73 Million EUR | -125.193% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -229.146% |
| Innate Pharma S.A. | 39.89 Million EUR | 56.321% |
| Inventiva S.A. | 37.4 Million EUR | 53.418% |
| MaaT Pharma SA | 14.07 Million EUR | -23.801% |
| MedinCell S.A. | 58.96 Million EUR | 70.447% |
| Nanobiotix S.A. | 50.56 Million EUR | 65.539% |
| Onward Medical N.V. | 16.87 Million EUR | -3.265% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -27.308% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 61.955% |
| Oxurion NV | 12.33 Million EUR | -41.276% |
| Pharming Group N.V. | 155.29 Million EUR | 88.779% |
| Poxel S.A. | 46.9 Million EUR | 62.846% |
| GenSight Biologics S.A. | 18.42 Million EUR | 5.443% |
| Transgene SA | 1.25 Million EUR | -1286.237% |
| Financière de Tubize SA | 79.2 Million EUR | 77.999% |
| UCB SA | 3.03 Billion EUR | 99.426% |
| Valneva SE | 208.81 Million EUR | 91.655% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -45755.263% |